3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
6
Rhabdomyosarcoma
5
Prostatic Neoplasms
5
Sarcoma, Synovial
3
Osteosarcoma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Liposarcoma
2
Leiomyosarcoma
2
Hemangiosarcoma
2
Head and Neck Neoplasms
2
Fibrosarcoma
2
Colorectal Neoplasms
2
Adrenocortical Carcinoma
2
Zollinger-Ellison Syndrome
1
Wilms Tumor
1
Uveal Melanoma
1
Unspecified Childhood Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Pinealoma
1
Interventions
Fluorouracil
218
Leucovorin
201
Oxaliplatin
191
Irinotecan
148
Bevacizumab
107
Capecitabine
93
Cetuximab
89
Folfox protocol
54
Chemotherapy, Adjuvant
34
Panitumumab
30
pembrolizumab
23
Nivolumab
22
Colonoscopy
22
Gemcitabine
20
Magnetic Resonance Spectroscopy
19
Floxuridine
19
IFL protocol
18
Celecoxib
18
Radiotherapy
17
Neoadjuvant Therapy
17
Early Intervention, Educational
17
Drug Therapy
17
Laparoscopy
14
Cyclophosphamide
14
Counseling
14
trifluridine tipiracil drug combination
13
regorafenib
13
XELOX
13
Exercise
13
Erlotinib Hydrochloride
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Colonic Neoplasms
×
cixutumumab
×
Clear all
NCT00845039
2018-07-02
FC-4
Eli Lilly and Company
Phase 2
Terminated
4 enrolled
9 charts